Objective: The objective of this study is to determine the incidence rate and risk factors of tuberculosis (TB) among HIV-infected adults accessing antiretroviral therapy (ART) in Tanzania.
Introduction
Tuberculosis (TB) continues to be a major public health threat globally, as an estimated 9.0 million new cases and 1.5 million TB deaths occurred worldwide in 2013 [1] . WHO estimates that one-third of the world's population is infected with the latent form of TB and therefore at risk of progressing to active TB. For most individuals, the initial infection is contained by host defenses, and the infection remains latent. However, among HIV-infected population, the risk of progression from latent TB to active TB is significantly higher. People living with HIV are 29 times more likely to develop active TB disease than HIV-negative and it is estimated that 1.1 million (13%) of the 9.0 million people who developed TB worldwide in 2013 were HIV-positive [1] .
Approximately 25 million people are living with HIV/ AIDS in sub-Saharan Africa [2] . The high HIV prevalence in this region has propagated a resurgence of both drug-susceptible and drug-resistant TB. According to a recent report by UNAIDS, over 75% of all estimated HIV-TB coinfected individuals live in just 10 countries, and nine of those countries are in sub-Saharan Africa [2] . The world has made substantial gains towards achieving the Millennium Development Goals (MDGs) of halving TB-related deaths among people living with HIV by 2015. From 2004 to 2012, TB-related deaths among people living with HIV declined by 36% worldwide [2] . However, TB continues to be the leading cause of death among people living with HIV, accounting for 25% of global HIV/AIDS-related deaths [1] . Antiretroviral therapy (ART) reduces the risk of active TB among people living with HIV [3, 4] . But longitudinal studies that include data on TB incidence in both pre-ART to post-ART initiation periods are limited. In a large, prospective cohort of HIV-infected patients attending HIV care and treatment in Dar es Salaam, Tanzania, we estimated TB incidence rates by ART status and determined risk factors associated with TB incidence.
Materials and methods

Study population
We conducted a prospective observational cohort study of HIV-infected individuals enrolled in the Management and Development for Health (MDH)-supported HIV care and treatment clinics in Tanzania. With financial support from the Presidents' Emergency Plan for AIDS Relief (PEPFAR), the MDH Program was established in 2004 as a joint partnership between Muhimbili University of Health and Allied Sciences, Dar es Salaam City Council, and Harvard University. The MDH programme provided infrastructure, laboratory and technical support to HIV care and treatment, integrated prevention of mother-to-child transmission of HIV and TB services in the three municipalities of Dar es Salaam: Temeke, Ilala and Kinondoni. From November 2004 to September 2012, 108 554 HIV-infected adults (!15 years of age) were enrolled in 47 MDH-supported HIV clinical sites. All patients received clinical care and treatment following national and WHO guidelines [5, 6] .
We excluded patients who had previously taken ART (n ¼ 8912), individuals who were diagnosed with TB within 30 days after enrolment (n ¼ 9711), individuals whose TB status was not recorded within 30 days after enrolment (n ¼ 6680), or those did not have any followup visits (n ¼ 15 565). After these exclusions, our final sample size was 67 686 patients ( Fig. 1 ). Among them, 53 056 (78%) were found eligible for and initiated ART during follow-up, the other 14 630 (22%) patients remained on care and monitoring services (ART-naive).
The institutional review boards for human research at the Harvard School of Public Health and the ethics review committees at Muhimbili University of Health and Allied Sciences in Dar es Salaam approved the study.
Antiretroviral therapy eligibility
Upon enrolment, each patient was assessed for eligibility for ART initiation. During the study period, ART initiation criteria for adults included the following: WHO stage IV, WHO stage III with CD4 þ cell count less than 350 cells/ml or CD4 þ cell count less than 200 cells/ ml. Antiretroviral drugs were provided free of charge by the Tanzanian government. Standard first-line ART regimens included two nucleoside reverse-transcriptase inhibitors (NRTIs) [lamivudine (3TC) or emtricitabine (FTC), as well as stavudine (d4T) or zidovudine (ZDV) or Tenofovir (TDF)], and one nonnucleoside reversetranscriptase inhibitor (NNRTI) [efavirenz (EFV) or nevirapine (NVP)]. To avoid drug interactions, EFV was substituted for NVP in patients receiving rifampin therapy for the treatment of TB. Patients who were not immediately eligible to initiate ART continued to receive routine care and monitoring service in the HIV clinics, and were started on ARTonce they met eligibility criteria [5, 6] . 
Participant assessments
In general, clinic visits were scheduled at 2 weeks of ART, then monthly thereafter for patients on ART, and 3 to 6-monthly for patients not receiving ART. Patients could come to clinics without an appointment during weekdays if necessary to seek extra care and treatment. At each clinic visit, patients were screened for TB on the basis of clinical symptoms, including cough, fever, night sweats, weight loss and haemoptysis. Sputum smears and chest radiographs were administered to all TB-suspected patients to assist with diagnosis. Physicians and nurses completed standardized forms to capture demographic and clinical information. Nurses used standardized techniques to obtain anthropometric measurements, including height, weight and middle upper arm circumference (MUAC). BMI was calculated as weight in kilograms divided by the square of the height in metres. Laboratory tests for CD4 þ cell counts, haemoglobin and alanine aminotransferase (ALT) concentrations were performed at enrolment, ART initiation and every 6 months during follow-up. Viral load testing was not routinely performed.
Study variables
Incident TB cases were defined as patients who were free of TB at enrolment and newly diagnosed with TB by sputum smear or chest radiograph, or prescribed anti-TB medications during follow-up. Demographic, clinical and nutritional characteristics were considered as independent variables, including age (<25, 25 to <35, 35 to <45, !45 years), sex (male/female), district of residence (Ilala, Kinondoni, Temeke), BMI (<17, 17 to <18.5, 18.5 to <25, 25 to <30, !30 kg/m 2 ), MUAC (<20, 20 to <22, 22 to <25, 25 to <27, !27 cm), anaemia (none, mild, moderate, severe), CD4 þ cell counts (<50, 50 to <100, 100 to <200, !200 cells/ml), WHO stage (I, II, III, IV), ALT ( 40, >40 U/l), pregnancy (no/yes), cotrimoxazole use (no/yes), isoniazid (INH) preventive therapy (no/yes), ART (no/yes). ART regimens were grouped according to their NRTI (d4T, ZDV or TDF) and NNRTI (EFV or NVP) agents. The use of INH has increased from 1.5 to 4.5% among patients over the 8 years of study period, and 2079 (3.1%) of the 67 686 patients in this study have received INH preventive therapy during the follow-up period. We grouped haemoglobin concentrations into the following categories according to WHO guidelines: severe anaemia (haemoglobin, <8.0 g/dl), moderate anaemia (8.0 to <11.0 g/dl), mild anaemia (11.0 to <13.0 g/dl for men and 11.0-12.0 g/dl for women), nonanaemia (!13.0 g/dl for men and !12.0 g/dl for women) [7] . Seasons of the clinical visit were categorized into long rainy (April-May), long dry (June-September) and short rainy (October-November), and short dry (December-March). Nonadherence was defined as more than 5% noncompliance with scheduled visits.
Statistical analysis
Incidence rates were calculated by number of new incident TB diagnosed divided by person-time followed up during non-ART and ART periods, respectively. Patients who have started ART during follow-up could contribute follow-up time to both non-ART and ART periods. Rates were presented per 100 person-years of follow-up, and 95% confidence intervals were calculated using exact Poisson probabilities. The primary outcome was time to first TB diagnosis after enrolment. The Andersen-Gill formulation of the Cox proportional hazard model was applied to evaluate the associations of each baseline characteristic measured at enrolment and selected time-varying parameters with time to first TB event after enrolment [8] . Patients who did not experience incident TB were censored at death or loss to follow-up or the last visit date by 30 September 2012. Missing indicator variables were created for covariates with incomplete information. Multivariate models were fit including all variables that were associated with the primary outcome with P value less than 0.20 in the univariate analysis. Likelihood ratio tests were used to calculate the P values for nominal variables, including district, season and calendar months. The possibility of nonlinear relations between continuous covariates and the risk of incident TB was examined nonparametrically with restricted cubic splines [9] . All statistical tests were two-sided, with P value less than 0.05 considered significant, and conducted using SAS 9.3 (Cary, North Carolina, USA).
Results
At enrolment, the mean (AEstandard deviation, SD) age was 35.6(AE9.7) years with 9% aged at least 50 years; approximately 25% were male. The mean BMI was 22.3(AE4.9) kg/m 2 , and 21% of the patients were underweight (defined by BMI <18.5 kg/m 2 ). The mean CD4 þ cell count was 268(AE239) cells/ml, and 51% were WHO HIV stage III or IV. These and other characteristics at enrolment are presented in Table 1 .
During the study period, 53 056 (78.4%) of 67 686 patients initiated ART, and the median time between enrolment and ART initiation was 31 [interquartile range (IQR), had a higher risk of developing TB than those enrolled in Ilala district. Patients enrolled in later calendar years tended to have a lower risk of TB than those enrolled in the earliest years of 2004-2005 when the HIV care and treatment programme started. Patients tended to have a relative higher risk of TB in the short rainy season (October-November). To further explore the seasonal pattern in TB risk, we examined the association of TB risk with calendar months and found that higher risk TB was observed in months of May, June and November, around the ends of the two rainy seasons in Dar es Salaam ( Fig. 2 , P < 0.001).
Time-varying nutritional status was significantly associated with TB risk. Compared with patients with normal BMI (18.5 to <25.0 kg/m 2 ), patients with BMI less than 17.0 had a two-fold increased risk of TB, while overweight and obese patients had 36 and 45% reduced risks, respectively (P value for trend <0.001). Similar associations were found between TB risk and MUAC (hazard ratio, 3.15; 95% CI, 2.86-3.46, comparing the lowest vs. highest categories; P value for trend < 0.001). Patients with severe, moderate and mild anaemia had 103, 66 and 22% higher risks of TB, respectively, than those without anaemia (P value for trend <0.001, Table 2 ).
Lower CD4 þ cell counts and advanced WHO HIV disease stage were significantly associated with a higher risk of developing TB. Compared with patients with CD4 þ cell count at least 350 cells/ml, those with CD4 þ cell count less than 200 cells/ml had a significantly 4-20% higher risk of TB. Compared with patients who were WHO stage I, those who were WHO stage II, III and IV had a 1.59, 3.54 and 3.44 times greater risk of TB, respectively (P for trend <0.001, Table 2) After controlling for potential confounders, patients in the first 3 months of ART had a 57% higher risk of developing TB than patients who were not on ART. However, the risk of TB began to decrease with continued ART, patients who were on ART for 3-6, 6-12, 12-24, 24-36, at least 36 months had a 21, 27, 46, 59 and 72% reduced risks of developing TB compared with patients who were not on ART ( Table 2) . Among patients who started ART, the relationship between risk of TB and months from ART Initiation were further demonstrated in Fig. 3 . From this graph, we observed that the risk of TB increased over time after enrolment and reached highest level around ART initiation, after that the risk decreased over time with increasing months on ART (Fig. 3) .
To compare the effect of different ART regimens on TB risk, a separate multivariate model was fit among patients who initiated ART during the follow-up period (n ¼ 53 056). Compared with patients receiving d4Tcontaning regimens, those receiving ZDV or TDFcontaining regimens had 35% (hazard ratio 0.65; 95% CI, 1394 AIDS 2015, Vol 29 No 11 
Discussion
In this large, observational, prospective cohort study of HIV-infected adults in Tanzania, we found that the incidence of TB was significantly lower for patients receiving ART than those who were not on ART. However, patients within the first 3 months following ART initiation had a temporary increased risk. Male sex, poor nutritional status, lower CD4 þ cell count and advanced HIV disease stage were associated with a higher risk of developing active TB. In addition, we found a seasonal fluctuation of TB incidence with a higher risk in the end of rainy seasons in Dar es Salaam, Tanzania (May, June and November).
It is well documented that ART effectively reduces TB incidence among population in HIV-endemic areas [3, 4, [10] [11] [12] . ART suppresses viral activity and promotes the restoration of the immune system, hence leading to a reduced risk of reactivating latent TB or of emerging opportunistic infections. However, TB incidence may rise during the initial months on ART, which is largely due to ART-induced unmasking of subclinical active TB and delayed diagnosis of unspecific symptomatic patients in resource-limited settings [13] [14] [15] . The TB incidence pattern following ART initiation in the current study is consistent with findings from previous studies [16] [17] [18] [19] [20] . Data from both South Africa [18, 20] and Nigeria [19] demonstrated that TB incidence was higher in the first year of ART, then decreased over time thereafter. Similar to our previous finding among HIV-infected children, patients receiving NVP-containing ART regimens had a lower risk of developing TB [21] . Due to the concerns over an advert drug interaction between NVP and rifampin (anti-TB therapy), EFV was recommend to replace NVP for TB-infected patients [5] . Therefore, the increased risk associated with EFV might be due to confounding by indication, meaning that patients who were suspected with TB infection but without enough evidence for diagnosis at ART initiation were more likely to be prescribed EFV-containing regimens.
Our study demonstrated that nutritional status is a strong predictor for TB risk among HIV-infected adults. The bidirectional association between malnutrition and TB has been well documented in general population [22, 23] . However, there has been little evidence among HIVinfected populations receiving ART [24] . Several studies have indicated that poor nutritional status is associated with higher risks of mortality and opportunistic infection, including TB, after ART initiation [25] [26] [27] . Furthermore, coinfection with HIV and TB exacerbates the malnutrition and wasting seen in TB or HIV infection alone, due to increased energy expenditure, decreased appetite and nutrient malabsorption [28, 29] . To exclude the possibility of reverse causality, patients diagnosed with active TB within 30 days after enrolment were excluded 1396 AIDS 2015, Vol 29 No 11 Only patients who started ART during the follow-up period were included into the analysis to examine the association of ART agents with TB risk.
from the current analysis. To clarify the temporal relationship between nutritional status and incident TB, the time-varying nutritional status indicators, measured by BMI, MUAC and haemoglobin level, were associated with outcomes at least 1 month later in our analyses. To control the high TB risk and sustain the ART treatment outcomes, randomized controlled trials are warranted to confirm findings from observational studies and identify effective strategies to improve and maintain nutritional status among HIV-infected individuals.
In this study, we also found that the risk of TB was higher at the end of rainy seasons (May, June and November). This may be due to people spending more time indoors during rainy seasons, thereby increasing close contact and exposure time to TB-infected individuals. The seasonal variation across the year might also be related to the seasonal fluctuation in vitamin D status. Several studies have suggested that vitamin D deficiency impairs the immune response to mycobacterial infection [30] . Evidence from observational studies has shown that vitamin D deficiency was associated with a higher risk of TB in various populations [31] [32] [33] [34] . In a previous study from Tanzania, Sudfeld et al. [35] found that the period of June through August was associated with the highest risk of low vitamin D status [25(OH)D <30 ng/ml] in HIVinfected adults. This finding is consistent with our result that the higher risk of TB was observed in the similar period from May to November. Randomized controlled trials of vitamin D supplementation for prevention of TB appear to be warranted for HIV-infected populations.
Consistent with published data, we identified several other risk factors for incident TB among HIV-infected population, including male, lower CD4 þ cell counts [18, 36, 37] and advanced HIV disease stage [18, 37] . We found that patients enrolled in Kinondoni and Temeke districts had a higher risk of TB than those enrolled in Ilala. In Dar es Salaam, people living in Ilala district tend to have a higher social economic status, which might be associated with lower prevalence and incidence of TB infection among the population.
Our study had several strengths and limitations. First, the majority of the TB diagnoses were based on clinical syndromes. Physicians ordered sputum smear test and chest X-ray for all diagnosed TB patients in this study, but only 12% of them had a positive result on sputum smear and 7% positive on chest X-ray. Sputum cultures were not available in the HIV care and treatment clinics in Dar es Salaam. Because of the high TB incidence among the target population, sputum microbiologic confirmation was not required for the diagnosis and treatment of TB for patients attending the HIV clinics. Second, as viral loads were not routinely measured in the study population, and socio-economic data and other lifestyle factors, including smoking and diet, were not collected, we were not able to take them into account and potential residual confounding from these factors cannot be excluded. The strengths of the study include the large sample size and relatively long follow-up period. More than 75% of the patients started ART during the follow-up and contributed data and person-years in both pre-ART and post-ART periods; this allows us to calculate the TB incidence by ART status and examine the both short-term and longterm effects of ART on TB incidence.
In summary, our findings demonstrate that ART significantly reduced the incidence of active TB among HIV-infected individuals, despite a sharp increase in TB incidence during the initial months of ART due to unmasking of subclinical TB. Malnutrition, lower CD4 þ cell counts and advanced WHO HIV disease state were significant predictors of TB incidence, while seasonal variation played a role in the development of TB among HIV-infected population. A combined strategy targeting for improving and maintaining nutritional status, effective TB screening tools, timely initiation of ART and controlling HIV disease progression is needed to reduce the high TB risk among HIV-infected population in resource-limited settings. In TB-endemic regions, patients initiating ART, particularly men and those with poor nutritional status, should be closely monitored for active TB in the months following ART initiation. Further studies focused on nutritional interventions in the context of ART and HIV/TB coinfection are warranted.
